SE451798B - Radioaktiv komposition innehallande indium-8-hydroxilandin och sett att merka blodceller - Google Patents
Radioaktiv komposition innehallande indium-8-hydroxilandin och sett att merka blodcellerInfo
- Publication number
- SE451798B SE451798B SE8009185A SE8009185A SE451798B SE 451798 B SE451798 B SE 451798B SE 8009185 A SE8009185 A SE 8009185A SE 8009185 A SE8009185 A SE 8009185A SE 451798 B SE451798 B SE 451798B
- Authority
- SE
- Sweden
- Prior art keywords
- indium
- radioactive
- solution
- solutions
- radioassay
- Prior art date
Links
- 230000002285 radioactive effect Effects 0.000 title claims description 18
- 239000000203 mixture Substances 0.000 title claims description 14
- 210000000601 blood cell Anatomy 0.000 title claims description 4
- 239000000243 solution Substances 0.000 claims description 41
- 229910052738 indium Inorganic materials 0.000 claims description 20
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 238000002372 labelling Methods 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 11
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 3
- 239000012857 radioactive material Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000013522 chelant Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 206010000269 abscess Diseases 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 241000283707 Capra Species 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000012503 blood component Substances 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229960003540 oxyquinoline Drugs 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AEGSYIKLTCZUEZ-UHFFFAOYSA-K tri(quinolin-8-yloxy)indigane Chemical compound [In+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 AEGSYIKLTCZUEZ-UHFFFAOYSA-K 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- -1 sodium chloride Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/108,575 US4348375A (en) | 1979-12-31 | 1979-12-31 | Radioassay process and compositions useful therein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8009185L SE8009185L (sv) | 1981-07-01 |
| SE451798B true SE451798B (sv) | 1987-11-02 |
Family
ID=22322962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8009185A SE451798B (sv) | 1979-12-31 | 1980-12-30 | Radioaktiv komposition innehallande indium-8-hydroxilandin och sett att merka blodceller |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4348375A (da) |
| JP (2) | JPS56103118A (da) |
| AT (1) | AT368889B (da) |
| BE (1) | BE886930A (da) |
| CA (1) | CA1155372A (da) |
| CH (1) | CH652308A5 (da) |
| DE (1) | DE3049533A1 (da) |
| DK (1) | DK556880A (da) |
| ES (1) | ES8202154A1 (da) |
| FR (1) | FR2474314A1 (da) |
| GB (1) | GB2066664B (da) |
| IT (1) | IT1193721B (da) |
| NL (1) | NL8007094A (da) |
| SE (1) | SE451798B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443426A (en) * | 1982-06-14 | 1984-04-17 | Yale University | Blood agent |
| AU580958B2 (en) * | 1983-07-07 | 1989-02-09 | Mallinckrodt, Inc. | Sterile radioactive indium-containing aqueous solution |
| US4672028A (en) * | 1984-05-23 | 1987-06-09 | Icn Micromedic Systems, Inc. | Compositions and method for simultaneous multiple array of analytes using radioisotope chelate labels |
| US5376356A (en) * | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| US5792444A (en) * | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| US5524622A (en) * | 1994-09-20 | 1996-06-11 | Oregon Health Sciences University | Non-invasive method of determining inflammation of the gastrointestinal tract |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017596A (en) * | 1975-03-03 | 1977-04-12 | Research Corporation | Radiopharmaceutical chelates and method of external imaging |
| CA1070695A (en) * | 1975-09-02 | 1980-01-29 | Michael D. Loberg | Iminodiacetic acid pharmaceutical |
| FR2390408A1 (fr) * | 1977-05-11 | 1978-12-08 | Philips France | Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus |
| US4335095A (en) * | 1979-03-21 | 1982-06-15 | The Radiochemical Centre Limited | Indium-111 oxine complex composition |
-
1979
- 1979-12-31 US US06/108,575 patent/US4348375A/en not_active Expired - Lifetime
-
1980
- 1980-12-30 CA CA000367724A patent/CA1155372A/en not_active Expired
- 1980-12-30 FR FR8027815A patent/FR2474314A1/fr active Granted
- 1980-12-30 GB GB8041472A patent/GB2066664B/en not_active Expired
- 1980-12-30 AT AT0635880A patent/AT368889B/de not_active IP Right Cessation
- 1980-12-30 DK DK556880A patent/DK556880A/da not_active Application Discontinuation
- 1980-12-30 CH CH9649/80A patent/CH652308A5/de not_active IP Right Cessation
- 1980-12-30 NL NL8007094A patent/NL8007094A/nl not_active Application Discontinuation
- 1980-12-30 IT IT69013/80A patent/IT1193721B/it active
- 1980-12-30 SE SE8009185A patent/SE451798B/sv not_active IP Right Cessation
- 1980-12-30 ES ES498236A patent/ES8202154A1/es not_active Expired
- 1980-12-31 DE DE19803049533 patent/DE3049533A1/de not_active Withdrawn
- 1980-12-31 BE BE0/203373A patent/BE886930A/fr not_active IP Right Cessation
- 1980-12-31 JP JP18946780A patent/JPS56103118A/ja active Pending
-
1989
- 1989-04-04 JP JP1084140A patent/JPH02117623A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES498236A0 (es) | 1982-01-01 |
| CH652308A5 (de) | 1985-11-15 |
| FR2474314B1 (da) | 1984-10-05 |
| GB2066664B (en) | 1984-06-20 |
| FR2474314A1 (fr) | 1981-07-31 |
| JPS56103118A (en) | 1981-08-18 |
| DK556880A (da) | 1981-07-01 |
| AT368889B (de) | 1982-11-25 |
| ES8202154A1 (es) | 1982-01-01 |
| IT8069013A0 (it) | 1980-12-30 |
| DE3049533A1 (de) | 1981-09-17 |
| NL8007094A (nl) | 1981-08-03 |
| ATA635880A (de) | 1982-04-15 |
| CA1155372A (en) | 1983-10-18 |
| BE886930A (fr) | 1981-04-16 |
| US4348375A (en) | 1982-09-07 |
| IT1193721B (it) | 1988-08-24 |
| SE8009185L (sv) | 1981-07-01 |
| GB2066664A (en) | 1981-07-15 |
| JPH02117623A (ja) | 1990-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rossen et al. | Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. | |
| EP0430968B1 (en) | Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles | |
| Dunn et al. | The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body's fluid compartments and secretions | |
| Beller et al. | Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate. | |
| Klonizakis et al. | Radionuclide Distribution folowing Injection of 111Indium‐labelled Platelets | |
| Fischer et al. | The tissue distribution and excretion of radioactive digitoxin: studies on normal rats and cats, and rats with dietary-induced myocardial lesions | |
| Tan et al. | Studies on the site of synthesis of transcobalamin-II | |
| US4443426A (en) | Blood agent | |
| US20070048216A1 (en) | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma | |
| SE451798B (sv) | Radioaktiv komposition innehallande indium-8-hydroxilandin och sett att merka blodceller | |
| Puchelle et al. | Rheology of sputum collected by a simple technique limiting salivary contamination | |
| Sellers et al. | Determination of extravascular albumin in the rat | |
| US4360509A (en) | Vivo radioassay process | |
| Thakur et al. | Evaluation of indium-111-2-mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation | |
| Barth et al. | Use of 99mTc as a radioisotopic label to study the migratory patterns of normal and neoplastic cells | |
| MacDonald et al. | Effect of serotonin upon liver cells of young rats. | |
| Handley et al. | Some pharmacological properties of three new mercurial diuretics. | |
| Bergmann et al. | Detection of cardiac transplant rejection with radiolabeled lymphocytes. | |
| Allwood | The migratory behavior of T blasts to contact sensitivity reactions in activelyand passively sensitized mice | |
| US3130189A (en) | Hydroxocobalamin-glutathione | |
| Wolff et al. | Correlation of physicochemical parameters and biological activity in steroids 9 α-substituted cortisol derivatives | |
| Goedemans et al. | Diagnostic compositions containing a chelate of radioactive indium and 8-hydroxyquinoline | |
| US4705678A (en) | Sterile radioactive indium-containing aqueous solution | |
| Jaakkola et al. | Labelling lymphocytes with technetium99m-hexamethyl propyleneamine oxime for scintigraphy: an improved labelling procedure | |
| Aikawa et al. | Distribution of Hg203-labeled mercaptomerin in organs of normal rabbits. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8009185-3 Effective date: 19910704 Format of ref document f/p: F |